基本情報
- CAS
92047-76-2- 標準SMILES
O.O=O.[O-][Cl+][O-].[O-][Cl+][O-].[O-][Cl+][O-].[O-][Cl+][O-]- InChIKey
HDWYUXFNUVEZOB-UHFFFAOYSA-N- 分子式
- Cl4H2O11-4
- 平均分子量
- 319.8 g/mol
- 単同位体質量
- 317.835122
概要
WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
名称と識別子
- 優先名称
- Tetrachlorodecaoxide
- IUPAC
- molecular oxygen;tetrachlorite;hydrate
名称と別名
TetrachlorodecaoxideTCDOTetrachlorodecaoxygen92047-76-2WF10DTXSID40238840420-970-2549BT7IE1QAncloximexAnimexanDac n-055Dermazoon
名称をさらに表示
DesopurDTXCID90161331ImmunokineMacrokineOxoferinOxomexanOxovasinOxovir
データベース識別子
- CAS
92047-76-2- PubChem CID
- 3000391
- DTXSID
DTXSID40238840- ChEMBL
CHEMBL6067985- EC Number
- 420-970-2
物性
構造計算による物性
- 極性表面積
- 196 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 11
- 回転可能結合数
- 0
- 重原子数
- 15
- 形式電荷
- -4
- 複雑度
- 7.5
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
危険有害性情報
Regulatory Information
REACH registered substance: Tetrachlorodecaoxide (EC: 420-970-2)
Tetrachlorodecaoxide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
化学と産業
薬理情報
Mechanism of Action
WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.
MeSH Pharmacological ClassificationDrugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…